Price
CHART BY
Frequently asked questions
What is Gubra's market capitalization?
What is the Earnings Per Share (EPS) for Gubra?
What are the analyst ratings and target price for Gubra's stock?
What is Gubra's revenue over the trailing twelve months?
What is the EBITDA for Gubra?
What is the free cash flow of Gubra?
How many employees does Gubra have, and what sector and industry does it belong to?
What is the free float of Gubra's shares?
Financials
- Market Cap
- $1.47B
- EPS (TTM)
- -$0.40
- Free Float
- 15.43M
- Revenue (TTM)
- $31.39M
- EBITDA (TTM)
- -$6.93M
- Free Cashflow (TTM)
- -$6.19M
Pricing
- 1D span
- $87.94$90.60
- 52W span
- $22.13$109.25
Analyst Ratings
The price target is $140.26 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Gubra A/S engages in providing research and development services to pharmaceutical and biotechnology companies on a contract basis. It operates through two business segments: Pre-clinical Contract Research (CRO), Discovery and Partnerships (D and P), and Gubra Green. The CRO segment refers to pre-clinical contract research and development services within metabolic and fibrotic diseases. The D and P segment include portfolio strategy in the form of upfront payments, research payments, milestone payments, and royalties. The Gubra Green segment relates to investments in targeting assets. The company was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Hørsholm, Denmark.
- Employees
- 219
- Industries
- Miscellaneous Commercial Services
- Sector
- Health Care
Identifier
- ISIN
- DK0062266474
- Primary Ticker
- GUBRA